Immunome bets on Nectin’s antibodies for next-generation antibody drug conjugates

Jul 23

The collaboration aligns with Immunome's strategy of pursuing under-explored targets for cancer drugs.

Eisbach Bio doses first patient in Phase 1/2 Trial for first-in-class drug to take on Refractory Advanced Solid Tumors